Guido Junge
Overview
Explore the profile of Guido Junge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nester C, Eisenberger U, Karras A, le Quintrec M, Lightstone L, Praga M, et al.
Kidney Int Rep
. 2025 Feb;
10(2):432-446.
PMID: 39990880
Introduction: C3 glomerulopathy (C3G) is a complex, chronic, ultra rare, progressive primary glomerulonephritis, resulting from alternative complement pathway overactivation, leading to kidney failure in most patients, and frequent recurrence in...
2.
Dorner T, Bowman S, Fox R, Mariette X, Papas A, Grader-Beck T, et al.
Arthritis Rheumatol
. 2024 Nov;
PMID: 39557617
Objective: The objective of this study was to report 52-week safety and efficacy of ianalumab from phase 2b dose-finding study in patients with Sjögren's disease (SjD). Methods: Patients randomly received...
3.
Gatlik E, Mehes B, Voltz E, Sommer U, Tritto E, Lestini G, et al.
Clin Transl Sci
. 2024 May;
17(5):e13789.
PMID: 38761014
This first-in-human study evaluated the safety, tolerability, single- and multiple-dose pharmacokinetic profiles with dietary influence, and pharmacodynamics (PD) of DFV890, an oral NLRP3 inhibitor, in healthy participants. In total, 122...
4.
Wong E, Nester C, Cavero T, Karras A, le Quintrec M, Lightstone L, et al.
Kidney Int Rep
. 2023 Dec;
8(12):2754-2764.
PMID: 38106570
Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability,...
5.
Zhang H, Rizk D, Perkovic V, Maes B, Kashihara N, Rovin B, et al.
Kidney Int
. 2023 Nov;
105(1):189-199.
PMID: 37914086
Targeting the alternative complement pathway is an attractive therapeutic strategy given its role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is an oral, proximal alternative complement inhibitor...
6.
Hakim A, Awili M, ONeal H, Siddiqi O, Jaffrani N, Lee R, et al.
Clin Exp Immunol
. 2023 Jun;
213(3):265-275.
PMID: 37338154
MAS825, a bispecific IL-1β/IL-18 monoclonal antibody, could improve clinical outcomes in COVID-19 pneumonia by reducing inflammasome-mediated inflammation. Hospitalized non-ventilated patients with COVID-19 pneumonia (n = 138) were randomized (1:1) to...
7.
Madurka I, Vishnevsky A, Soriano J, Gans S, Ore D, Rendon A, et al.
Infection
. 2022 Sep;
51(3):641-654.
PMID: 36104613
Background: Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm. Methods: This randomised, multinational study...
8.
Jang J, Wong L, Ko B, Yoon S, Li K, Baltcheva I, et al.
Blood Adv
. 2022 May;
6(15):4450-4460.
PMID: 35561315
Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH). In this ongoing open-label phase 2 study, PNH patients with...
9.
Bowman S, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T, et al.
Lancet
. 2021 Dec;
399(10320):161-171.
PMID: 34861168
Background: Sjögren's syndrome is an autoimmune disease characterised by dry eyes and mouth, systemic features, and reduced quality of life. There are no disease-modifying treatments. A new biologic, ianalumab (VAY736),...
10.
Risitano A, Roth A, Soret J, Frieri C, Sicre de Fontbrune F, Marano L, et al.
Lancet Haematol
. 2021 Mar;
8(5):e344-e354.
PMID: 33765419
Background: The haematological benefit of standard-of-care anti-C5 treatment for haemolytic paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or emerging C3-mediated extravascular haemolysis. Therefore, the aim of this phase...